Labiotech.eu

Interview 22 Jun 2017

Live Labiotech Hangout: Join our second webcast on synthetic biology, entrepreneurship and academia!

Join us for our second live Hangout with serial synbio entrepreneur but determined academic, Morten Sommer, which will be streaming live next week Thursday June 29th at 5:00pm CET! Click to Join the Hangout We can’t wait for an event to produce videos for our readers, and we realized we don’t have to! Next week is the second […]

June 22, 2017 - 1 minutemin - By Evelyn Warner

Novartis Cardiovascular Canakinumab Phase III

News and Trends 22 Jun 2017

Novartis Scores Major Phase III Win with New Cardiovascular Drug

Novartis just announced that its anti-inflammatory drug, canakinumab, was able to clear a 10,000-plus patient Phase III trial for cardiovascular disease. Novartis most recently boasted impressive Phase III results for its AMD drug, RTH258, that could yield the company a new blockbuster. Now, the Swiss drug maker announced that its cardiovascular drug, canakinumab, was able to meet its primary endpoint in […]

June 22, 2017 - 2 minutesmins - By Melanie De Almeida

Ose Immunotherapeutics bpifrance milestone bowel disease

News and Trends 22 Jun 2017

Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance

OSE Immunotherapeutics has successfully completed the necessary milestones to bring a treatment for autoimmune disease to the clinic, triggering a milestone payment from its partner Bpifrance. OSE Immunotherapeutics, based in Nantes, France, has received €2.6M from the French public investment agency Bpifrance after completing another milestone in the development of a therapy for inflammatory bowel disease. […]

June 22, 2017 - 1 minutemin - By Clara Rodríguez Fernández

cancer research uk grand challenge award

News and Trends 22 Jun 2017

What are the Biggest Cancer Challenges? The UK Offers £20M Prizes for Solutions!

Cancer Research UK is taking applications for £20M prizes from research groups worldwide that want to solve the biggest challenges in cancer research. Cancer Research UK is launching today its second round of the Grand Challenge to tear down some of the biggest barriers to the advancement of cancer therapy. The charity will shortlist the most promising […]

June 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Jun 2017

LAB282 Awards Second Funding Round to 5 Academic Projects at Oxford

Evotec and the University of Oxford have announced the academic projects that will receive a financial award to push them towards launching spin-outs. LAB282 is a partnership between the German biotech Evotec, Oxford University Innovation and Oxford Sciences Innovation, the University’s venture fund manager. Set up with the aim to bridge academia and industry in life sciences, LAB282 […]

June 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 21 Jun 2017

Video: Can Synbio Cure Malaria? – Fireside Chat with Oxitec’s CEO Hadyn Parry

In our fireside chat with Hadyn Parry, Clara had the chance to hear all about Oxitec’s exciting technology that could save us from Dengue and Zika. Oxitec’s GM mosquitoes have the potential to halt epidemics of mosquito-borne diseases such as Zika or Dengue, which according to Hadyn are actually causing more problems every year. As Hadyn explained, “we’re […]

June 21, 2017 - 3 minutesmins - By Melanie De Almeida

Cell Medica Catapult Therapy TCR Acquisition

News and Trends 21 Jun 2017

British Biotech Tops up its Cancer Pipeline with New TCR Therapy

Cell Medica just acquired Catapult Therapy TCR, set up by UK’s CGT Catapult, gaining the rights to its TCR therapy candidate to treat solid tumors. Cell Medica says it’s all set to leverage its Dominant T cell receptor (TCR) platform technology, which the company licensed from University College London (UCL) last year, to enhance existing T cell […]

June 21, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 21 Jun 2017

Swedish IPO raises €51M for Biomaterials to Repair Bone

Bonesupport has gone public in the Swedish stock market to push its pipeline and increase sales of biomaterials to regenerate bone tissue. Bonesupport is a company based in Lund, Sweden, that develops biomaterials to improve and speed up the repair of bones. The firm IPO’d today on the Nasdaq Stockholm, raising an impressive €51M with the participation […]

June 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Infographics 21 Jun 2017

Check Out these 42 European SynBio Startups Reimagining the Industry

Synthetic biology, or synbio for short, is rapidly infiltrating multiple fields. From bioplastics to food technology and healthcare, these are the startups in Europe that are expanding the frontiers of what synbio can do to improve our lives in many different ways. In the not-so-distant future, synthetic biology could bring us anything from spider silk […]

June 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 20 Jun 2017

Swedish Biotech publishes Long-Term Data on a Dendritic Cell Therapy for Cancer

Immunicum has reported new data on long-term follow-up of patients treated with ilixadencel, a unique dendritic cell therapy against cancer. Immunicum is a Swedish biotech developing a cell-based therapy against cancer. The company has just published in the Journal for Immunotherapy for Cancer detailed results from a Phase I/II trial evaluating its lead candidate ilixadencel. The cell […]

June 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Jun 2017

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Bayer’s and Regeneron’s blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD) market since its Roche-partnered VEGF-A inhibitor Lucentis was outperformed by Eylea from Bayer and Regeneron, which required a less-frequent dosing schedule and was placed at a lower […]

June 20, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 20 Jun 2017

Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma

argenx’s 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn’t been disclosed by how much exactly. Two years ago, Ghent-based argenx and Danish Leo Pharma teamed up to develop antibodies to counter inflammatory diseases in a deal totalling €105M. argenx just received its second preclinical milestone for granting Leo access to […]

June 20, 2017 - 1 minutemin - By Evelyn Warner

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Live Labiotech Hangout: Join our second webcast on synthetic biology, entrepreneurship and academia!

Novartis Scores Major Phase III Win with New Cardiovascular Drug

Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance

What are the Biggest Cancer Challenges? The UK Offers £20M Prizes for Solutions!

LAB282 Awards Second Funding Round to 5 Academic Projects at Oxford

Video: Can Synbio Cure Malaria? – Fireside Chat with Oxitec’s CEO Hadyn Parry

British Biotech Tops up its Cancer Pipeline with New TCR Therapy

Swedish IPO raises €51M for Biomaterials to Repair Bone

Check Out these 42 European SynBio Startups Reimagining the Industry

Swedish Biotech publishes Long-Term Data on a Dendritic Cell Therapy for Cancer

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!